TY - JOUR
T1 - Pushing the boundaries of radiotherapy-immunotherapy combinations
T2 - highlights from the 7th immunorad conference
AU - Laurent, Pierre Antoine
AU - André, Fabrice
AU - Bobard, Alexandre
AU - Deandreis, Desiree
AU - Demaria, Sandra
AU - Depil, Stephane
AU - Eichmüller, Stefan B.
AU - Fernandez-Palomo, Cristian
AU - Foijer, Floris
AU - Galluzzi, Lorenzo
AU - Galon, Jérôme
AU - Guckenberger, Matthias
AU - Harrington, Kevin J.
AU - Herrera, Fernanda G.
AU - Huber, Peter E.
AU - Italiano, Antoine
AU - Karam, Sana D.
AU - Kroemer, Guido
AU - Lambin, Philippe
AU - Leuschner, Carola
AU - Mantovani, Alberto
AU - Meylan, Etienne
AU - Mondini, Michele
AU - Pittet, Mikael J.
AU - Pouget, Jean Pierre
AU - Remon, Jordi
AU - Sørensen, Claus S.
AU - Sotiriou, Christos
AU - Vanpouille-Box, Claire
AU - Weichselbaum, Ralph R.
AU - Welsh, James W.
AU - Zitvogel, Laurence
AU - Formenti, Silvia C.
AU - Deutsch, Eric
N1 - Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.
AB - Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.
KW - Cancer
KW - FLASH radiotherapy
KW - T cells
KW - immune checkpoint
KW - immunorad
KW - immunotherapy
KW - low-dose radiotherapy
KW - lymph-node sparing
KW - radiotherapy
KW - tumor-associated macrophages
UR - http://www.scopus.com/inward/record.url?scp=85212767581&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2024.2432726
DO - 10.1080/2162402X.2024.2432726
M3 - Article
AN - SCOPUS:85212767581
SN - 2162-4011
VL - 14
JO - OncoImmunology
JF - OncoImmunology
IS - 1
M1 - 2432726
ER -